FDA approves first gene therapy for pediatric Sanfilippo syndrome Type A
The FDA approved Fayuvi (rebisufligene etisparvovec‑hopf) as a one‑time intravenous gene therapy for pediatric patients with mucopolysaccharidosis type III…
Impact analysis · 50/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The FDA approved Fayuvi (rebisufligene etisparvovec‑hopf) as a one‑time intravenous gene therapy for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A). The approval is full (standard) and is granted after prior orphan drug, fast track, and breakthrough designations. Effects were measured versus historical control data.
Quantitative evidence
- one‑time IV administration
- pediatric patients aged 2 to 5 years
- historical control comparison of cognitive function
- exact n in study
- quantitative magnitude of cognitive benefit
- p‑values or confidence intervals
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
This approval represents the first ever gene therapy targeting the underlying SGSH enzyme deficiency using systemic AAV9 vector delivery to the CNS in pediatric patients with MPS IIIA.
Market context
Ultragenyx, now with a second gene therapy approval, gains a novel asset for a rare pediatric disease with no prior disease‑modifying options.
Legal and regulatory context
This is a final FDA approval following orphan drug, fast track, and breakthrough designations.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- 1b98bdc8ceccf2876d7f584058f900d5bc9c995c365b91a55b938af0c8bb797a
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-09-17T213012Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.